These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25168847)

  • 1. Lipid and blood pressure control for the prevention of cardiovascular disease in hypertensive patients: a subanalysis of the OMEGA study.
    Teramoto T; Kawamori R; Miyazaki S; Teramukai S; Sato Y; Okuda Y; Shirayama M
    J Atheroscler Thromb; 2015; 22(1):62-75. PubMed ID: 25168847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.
    Teramoto T; Kawamori R; Miyazaki S; Teramukai S; Mori Y; Okuda Y; Hiramatsu K;
    Clin Exp Hypertens; 2014; 36(4):236-43. PubMed ID: 23865387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study.
    Teramoto T; Kawamori R; Miyazaki S; Teramukai S; Shirayama M; Hiramatsu K; Kobayashi F;
    Hypertens Res; 2012 Dec; 35(12):1136-44. PubMed ID: 22763478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients.
    Schmieder RE; Böhm M
    J Hum Hypertens; 2011 Jun; 25(6):354-63. PubMed ID: 20686499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults.
    Takeuchi T; Nemoto K; Takahashi O; Urayama KY; Deshpande GA; Izumo H
    J Clin Lipidol; 2014; 8(5):501-9. PubMed ID: 25234563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of plasma lipidomics in studying the response of patients with essential hypertension to antihypertensive drug therapy.
    Hu C; Kong H; Qu F; Li Y; Yu Z; Gao P; Peng S; Xu G
    Mol Biosyst; 2011 Dec; 7(12):3271-9. PubMed ID: 22009255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease].
    Cordero A; Bertomeu-Martínez V; Mazón P; Fácila L; Bertomeu-González V; Cosín J; Galve E; Núñez J; Lekuona I; González-Juanatey JR
    Rev Esp Cardiol; 2011 Jul; 64(7):587-93. PubMed ID: 21640460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):328-39. PubMed ID: 23181738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
    Ghandehari H; Kamal-Bahl S; Wong ND
    Am Heart J; 2008 Jul; 156(1):112-9. PubMed ID: 18585505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined association of lipids and blood pressure in relation to incident cardiovascular disease in the elderly: the cardiovascular health study.
    Wong ND; Lopez VA; Roberts CS; Solomon HA; Burke GL; Kuller L; Tracy R; Yanez D; Psaty BM
    Am J Hypertens; 2010 Feb; 23(2):161-7. PubMed ID: 19927131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
    Nishiwaki M; Ikewaki K; Ayaori M; Mizuno K; Ohashi Y; Ohsuzu F; Ishikawa T; Nakamura H;
    J Cardiol; 2013 Mar; 61(3):196-200. PubMed ID: 23265677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction.
    Hermida RC; Ayala DE; Fernández JR; Mojón A
    Chronobiol Int; 2013 Mar; 30(1-2):68-86. PubMed ID: 23181592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes.
    Moyá A; Crespo JJ; Ayala DE; Ríos MT; Pousa L; Callejas PA; Salgado JL; Mojón A; Fernández JR; Hermida RC;
    Chronobiol Int; 2013 Mar; 30(1-2):116-31. PubMed ID: 23181613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.